Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery

Publication date: 15 March 2017 Source:International Journal of Pharmaceutics, Volume 519, Issues 1–2 Author(s): A. Sofia Silva, Ana M. Sousa, Renato P. Cabral, Marta C. Silva, Clarinda Costa, Sónia P. Miguel, Vasco D.B. Bonifácio, Teresa Casimiro, Ilídio J. Correia, Ana Aguiar-Ricardo Functionalized gold nanoparticles (AuNPs) have been widely investigated as promising multifunctional nanosystems for the theragnosis of lung cancer, the most common and prominent cause of cancer death worldwide. Nevertheless, nanoparticles are not in appropriate sizes for an accurate deep lung delivery and the lack of locally and effective delivery of therapeutic biomolecules to the deep lungs is, in fact, the major cause of low therapeutic outcome. Herein we incorporate, for the first time, AuNPs into respirable microparticles. AuNPs were functionalized with biocompatible oligo(2-oxazoline)-based optically stable fluorescent coatings, and conjugated with a laminin peptide (YIGSR) for targeted lung cancer delivery. These POxylated AuNPs were then incorporated into a chitosan matrix by a clean process, supercritical CO2-assisted spray drying (SASD), yielding nano-in-micro clean ultrafine dry powder formulations. The engineered formulations present the adequate morphology and flowability to reach the deep lung, with aerodynamic sizes ranging 3.2–3.8μm, and excellent fine particle fraction (FPF) (FPF of 47% for CHT-bearing targeted AuNPs). The optimal biodegrad...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
David R. Gandara, MD, shares exciting new developments in lung cancer at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
ConclusionsLncRNA XLOC_009167 could serve as a novel diagnostic biomarker to distinguish lung cancer from benign lung disease and healthy controls.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
We report on sessions on immunotherapies for non-small-cell lung cancer and pancreatic cancer from AACR and on endometriosis, hypoactive sexual desire disorder, neonatal abstinence syndrome, and more from ACOG. PMID: 30013302 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
Publication date: Available online 18 July 2018Source: Genomics, Proteomics &BioinformaticsAuthor(s): Ji Zhang, Xiao Han, Chunchun Gao, Yurong Xing, Zheng Qi, Ruijuan Liu, Yueqin Wang, Xiaojian Zhang, Yun-Gui Yang, Xiangnan Li, Baofa Sun, Xin TianAbstractNon-small-cell lung cancer (NSCLC), the most common type of lung cancer accounting for 85% of the cases, is often diagnosed at advanced stages owing to the lack of efficient early diagnostic tools. 5-Hydroxymethylcytosine (5hmC) signatures in circulating cell-free DNA (cfDNA) that carries the cancer-specific epigenetic patterns may represent the valuable biomarkers for...
Source: Genomics, Proteomics and Bioinformatics - Category: Bioinformatics Source Type: research
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell lung cancer (NSCLC) at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Authors: Gong Q, Cao X, Cao J, Yang X, Zeng W Abstract Casticin, a natural polymethoxyflavone isolated from A. annua, V. trifolia, and V. agnus‑castus induces apoptosis in cancer cells by activating FoxO3a. However, whether casticin inhibits in vitro carcinogenesis and cancer stem cell (CSC) characteristics, and whether casticin activates FoxO3a in small cell lung cancer (SCLC) cells remain unclear. We here demonstrated that casticin decreased sphere‑ and colony‑formation capabilities, and downregulated uPAR and CD133 in second‑generation spheres, which were considered as lung cancer ste...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Caveolin‑1 enhances RANKL‑induced gastric cancer cell migration. Oncol Rep. 2018 Jul 05;: Authors: Wang Y, Song Y, Che X, Zhang L, Wang Q, Zhang X, Qu J, Li Z, Xu L, Zhang Y, Fan Y, Hou K, Liu Y, Qu X Abstract The classical pathway involving receptor activator of nuclear factor‑κB (RANK) and its ligand (RANKL) induces the activation of osteoclasts and the migration of a variety of tumor cells, including breast and lung cancer. In our previous study, the expression of RANK was identified on the surface of gastric cancer cells, however, whether the RANKL/RANK pathway is involved in the regula...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
ESE‑1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in vivo. Oncol Rep. 2018 Jul 12;: Authors: Lou Z, Lee BS, Ha T, Xu Y, Kim HJ, Kim CH, Lee SH Abstract Lung cancer is the first leading cause of cancer‑related death in the United States. Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with a poor patient prognosis. Identification of promising molecular targets is required for the effective prevention and therapy of NSCLC. Epithelial‑specific ETS‑1 (ESE‑1) belongs to the superfamily of ETS transcriptio...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Growth inhibition of KRAS‑ and EGFR‑mutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis. Oncol Rep. 2018 Jul 02;: Authors: Onodera K, Sakurada A, Notsuda H, Watanabe T, Matsuda Y, Noda M, Endo C, Okada Y Abstract The need for effective treatment of KRAS‑mutant lung cancer is an emerging issue. Rho GTPase‑activating protein 35 (ARHGAP35) is reported to be a possible molecular target for lung adenocarcinoma. We investigated the effect of long‑term ARHGAP35 suppression on the proliferation, migration and molecular dynamics of lung adenocarcinomas harboring KRAS an...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Nanotechnology